About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Extracorporeal CO2 Removal in COPD Exacerbation

NCT01422681·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University of Turin, Italy

Age

18–90

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

COPD
severe acute respiratory failure
after at least two hours of continuous application of non-invasive ventilatory support (NIV):
arterial pH ≤7.30 with an arterial pressure of CO2 (PaCO2) \>20% of the baseline value and one of the following:
respiratory rate ≥30 breaths/min;
use of accessory muscles or paradoxical abdominal movements

You may not be if

failure to obtain consent
hemodynamic instability (MAP \< 60 mmHg) despite infusion of vasoactive drugs
contraindications to the administration of i.v. heparin (heparin induced thrombocytopenia, hemorrhage, etc.)
body weight \>120 kg
contraindication to continuation of active treatment (DNR)

The record

StatusCompleted

PhasePhase 2

Taking part30

StartedMay 2011

UpdatedJan 22, 2014

Conditions

COPD Exacerbation

Where1

University of Turin, Department of Anesthesia and Intensive Care Medicine
Turin, Italy, Italy

Clareo Health | Extracorporeal CO2 Removal in COPD Exacerbation